Latanoprostene Bunod
Overview
Latanoprostene bunod is a prostaglandin analog used topically in the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a nitric oxide-donating prodrug of latanoprost, which primarily works by remodeling the trabecular meshwork to enhance aqueous humor outflow.
API suppliers (6)
Suppliers of Latanoprostene Bunod evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 5 of 6 suppliers.
3 of 6 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- CAYMAN PHARMA SROCzechia1 active DMF GMP on record
- CHIROGATE INTERNATIONAL INCTaiwan1 active DMF
- EVERLIGHT CHEMICAL INDUSTRIAL CORPTaiwan1 active DMF
- YS LIFE SCIENCE CO LTD1 active DMF
- NEWCHEM SPAItaly1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Latanoprostene Bunod expires 21 Feb 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Latanoprostene Bunod? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.